- Home
- SM vs LGND Comparison
SM vs LGND Comparison
Compare SM & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- LGND
- Stock Information
- Founded
- SM 1908
- LGND 1987
- Country
- SM United States
- LGND United States
- Employees
- SM N/A
- LGND 68
- Industry
- SM Oil & Gas Production
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- SM Energy
- LGND Health Care
- Exchange
- SM Nasdaq
- LGND Nasdaq
- Market Cap
- SM 3.0B
- LGND 3.2B
- IPO Year
- SM 1992
- LGND 1992
- Fundamental
- Price
- SM $21.74
- LGND $180.56
- Analyst Decision
- SM Hold
- LGND Strong Buy
- Analyst Count
- SM 11
- LGND 8
- Target Price
- SM $40.78
- LGND $144.71
- AVG Volume (30 Days)
- SM 2.7M
- LGND 139.7K
- Earning Date
- SM 11-04-2025
- LGND 08-05-2025
- Dividend Yield
- SM 3.68%
- LGND N/A
- EPS Growth
- SM 1.83
- LGND N/A
- EPS
- SM 7.07
- LGND N/A
- Revenue
- SM $3,002,621,000.00
- LGND $181,488,000.00
- Revenue This Year
- SM $33.13
- LGND $18.41
- Revenue Next Year
- SM N/A
- LGND $18.87
- P/E Ratio
- SM $3.07
- LGND N/A
- Revenue Growth
- SM 27.02
- LGND 53.40
- 52 Week Low
- SM $19.67
- LGND $81.74
- 52 Week High
- SM $46.42
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- SM 31.05
- LGND 62.75
- Support Level
- SM $22.38
- LGND $177.76
- Resistance Level
- SM $25.67
- LGND $186.40
- Average True Range (ATR)
- SM 1.05
- LGND 5.03
- MACD
- SM -0.38
- LGND -0.73
- Stochastic Oscillator
- SM 8.18
- LGND 71.02
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.